Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹7,387 Cr
Revenue (TTM)
₹2,803 Cr
Net Profit (TTM)
₹360 Cr
ROE
16.9 %
ROCE
22.5 %
P/E Ratio
20.5
P/B Ratio
2.6
Industry P/E
--
EV/EBITDA
11.3
Div. Yield
0.5 %
Debt to Equity
0
Book Value
₹61.8
EPS
₹8
Face value
1
Shares outstanding
453,163,746
CFO
₹1,308.01 Cr
EBITDA
₹2,493.13 Cr
Net Profit
₹1,719.25 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Marksans Pharma
| -10.5 | -10.9 | -11.1 | -20.4 | 32.9 | 24.8 | 12.5 |
|
BSE Healthcare
| -4.0 | -3.8 | -4.0 | 3.0 | 24.6 | 15.5 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Marksans Pharma
| -40.8 | 84.7 | 176.6 | -3.2 | -1.3 | 253.6 | -40.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Marksans Pharma
|
161.4 | 7,386.6 | 2,803.3 | 361.8 | 15.5 | 14 | 20.5 | 2.6 |
| 160.3 | 2,562.6 | 2,796.8 | 118.8 | 8.1 | 2.3 | 21.6 | 0.4 | |
| 28.4 | 8.7 | 0.5 | 0.0 | 8.3 | -1.1 | -- | 2.2 | |
| 445.7 | 10,711.0 | 3,262.7 | 439.0 | 15.3 | 16 | 24.4 | 3.6 | |
| 52.6 | 192.2 | 133.8 | -0.3 | -0.7 | -0.6 | -- | 1.9 | |
| 21.4 | 644.4 | 1,450.4 | 47.9 | 6.6 | 10.1 | 14.4 | 1.4 | |
| 1,008.8 | 21,334.6 | 2,169.9 | 332.9 | 20.9 | 15.4 | 64.1 | 9.0 | |
| 4,217.7 | 9,735.5 | 878.4 | 240.1 | 33.8 | 73.3 | 40.5 | 25.4 | |
| 38.1 | 564.1 | 0.0 | 1.6 | -- | -0.5 | 350.6 | 21.0 | |
| 25.0 | 54.7 | 51.4 | 4.5 | 22.0 | 5.2 | 12.1 | 0.6 |
No Review & Analysis are available.
Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic... hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India. Read more
Incorporated
1992
Chairman
Mark Saldanha
Managing Director
Mark Saldanha
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Marksans Pharma Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The share price of Marksans Pharma Ltd is ₹161.41 (NSE) and ₹161.30 (BSE) as of 19-Mar-2026 15:58 IST. Marksans Pharma Ltd has given a return of 32.88% in the last 3 years.
The P/E ratio of Marksans Pharma Ltd is 20.50 times as on 19-Mar-2026.
The P/B ratio of Marksans Pharma Ltd is 2.64 times as on 19-Mar-2026, a 514 premium to its peers’ median range of 0.43 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
26.48
|
4.08
|
|
2024
|
21.89
|
3.33
|
|
2023
|
11.99
|
1.83
|
|
2022
|
10.10
|
1.68
|
|
2021
|
8.67
|
2.31
|
The 52-week high and low of Marksans Pharma Ltd are Rs 270.70 and Rs 156.00 as of 19-Mar-2026.
Marksans Pharma Ltd has a market capitalisation of ₹ 7,387 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Marksans Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-6.48
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.